Natural killer cell

Therapeutic Solutions International Universal Donor Immunotherapy StemVacs™ Activates Antiviral Immune Cells While Protecting Lungs From "Cytokine Storm"

Tuesday, June 30, 2020 - 3:35pm

StemVacs is a cell-based drug comprised of dendritic cells activated in a proprietary manner which when administered stimulates a type of immune system cell termed "natural killer" or NK cells.

Key Points: 
  • StemVacs is a cell-based drug comprised of dendritic cells activated in a proprietary manner which when administered stimulates a type of immune system cell termed "natural killer" or NK cells.
  • Numerous studies have shown that NK cells are involved in protecting the body from cancer and from viruses.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
  • Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system.

Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer

Friday, June 26, 2020 - 5:00am

Artiva will use the proceeds of this financing to develop off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor targeting CAR-NK cell therapies.

Key Points: 
  • Artiva will use the proceeds of this financing to develop off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor targeting CAR-NK cell therapies.
  • Artivas pipeline of universal and targeted NK cell therapies leverages the innate anti-tumor biology and safety features of NK cells.
  • Artivas proven executive team brings deep, diverse cell therapy and oncology experience to research and advance a pipeline of NK and CAR-NK cell therapies to treat cancer.
  • Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the companys unique manufacturing and engineering capabilities.

Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resistant IL-18 Cytokine

Thursday, June 25, 2020 - 2:45pm

NK cells quickly become exhausted and lose efficacy when confronted with tumor cells deficient in MHC Class 1.

Key Points: 
  • NK cells quickly become exhausted and lose efficacy when confronted with tumor cells deficient in MHC Class 1.
  • Single cell RNA sequencing and flow cytometry revealed that DR-18 promoted functional maturation of highly proliferative NK cells.
  • These results highlight DR-18s ability to remodel the intratumoral ecosystem to encourage the proliferation of potent anti-tumor effector cells.
  • Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.

Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II

Monday, June 22, 2020 - 2:52pm

The findings were presented in two posters at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II.

Key Points: 
  • The findings were presented in two posters at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II.
  • The findings presented today highlight the exciting potential of gene editing to add additional punch to the tumor killing properties of engineered NK cells and address the inhibitory checkpoints of the tumor microenvironment.
  • In addition, we are encouraged by the early observation of beneficial effects when CAR NK cells and CAR T cells are combined as a potential NK Plus T anti-cancer therapeutic.
  • The findings showed that gene editing can be combined with engineering to enhance NK cell function and resist the inhibitory action of the tumor microenvironment.

Silverback Therapeutics to Present Preclinical Data on SBT6050 Demonstrating Potent Activation of Human Myeloid Cells and the Potential for Single Agent Clinical Activity

Monday, June 22, 2020 - 2:00pm

In preclinical studies, SBT6050 activates human myeloid cells in the presence of HER2 expressing tumor cells, resulting in proinflammatory cytokine and chemokine production, inflammasome activation, and the indirect activation of cytolytic activity associated with T and NK cells.

Key Points: 
  • In preclinical studies, SBT6050 activates human myeloid cells in the presence of HER2 expressing tumor cells, resulting in proinflammatory cytokine and chemokine production, inflammasome activation, and the indirect activation of cytolytic activity associated with T and NK cells.
  • Robust, durable single agent activity is observed with the SBT6050 mouse surrogate in multiple tumor models, including those with low tumor infiltrating lymphocytes.
  • In a human xenograft model lacking T, B, and NK cells, the SBT6050 mouse surrogate is curative as a single agent, demonstrating the ability of myeloid cells to mediate strong anti-tumor activity.
  • Our preclinical data highlight SBT6050s potential to maximize anti-tumor immune responses, even in tumors lacking T cells.

SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II

Monday, June 22, 2020 - 2:00pm

The data were presented in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.

Key Points: 
  • The data were presented in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.
  • SO-C101 is a highly promising modality in immuno-oncology given its ability to mobilize the two most important cell types driving anti-cancer immune responses, NK cells and CD8+ T cells.
  • SO-C101 in combination with PD-1 inhibition prevents tumor development in TRAMP-C2 mice and delays tumor growth upon a re-challenge with tumor cells.
  • Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is a sponsor of the Phase 1 clinical trial.

Japanese Dietary Supplement: Nichi Glucan, an Immune Booster in Covid-19

Wednesday, June 17, 2020 - 8:19am

This AFO-202 strain produced Nichi Glucan enhanced the immunity by increasing Natural Killer (NK) cells and anti-viral cytokines of healthy people, cancer patients and elderly, in three different studies in Japan.

Key Points: 
  • This AFO-202 strain produced Nichi Glucan enhanced the immunity by increasing Natural Killer (NK) cells and anti-viral cytokines of healthy people, cancer patients and elderly, in three different studies in Japan.
  • Nichi Glucan is manufactured in a GMP factory in the banks of upstream Niyodo river in Kochi prefecture.
  • Approved as food additive in 1996 after conforming to all safety norms of Japanese standards, Nichi Glucan isnt a drug or cure to any illness.
  • Further research is underway to develop newer versions with higher adhesion for improvised immune stimulation.

Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus

Thursday, June 11, 2020 - 2:00pm

T cells are the adaptive immune system's first responders to detect any virus.

Key Points: 
  • T cells are the adaptive immune system's first responders to detect any virus.
  • An in-depth understanding of the T cell response to the COVID-19 virus has a variety of different applications.
  • As Adaptive generates these data, subsequent updates to ImmuneCODE will provide an increasingly clearer picture of the immune response to the COVID-19 virus.
  • ImmuneCODE is an open database that provides a detailed population-level view into the adaptive immune response to the COVID-19 virus.

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS

Thursday, June 11, 2020 - 2:00pm

The Phase I trial, calledLaurel,will include at least 9 patients enrolled at a single center in the UK and has the capacity for an extension cohort.

Key Points: 
  • The Phase I trial, calledLaurel,will include at least 9 patients enrolled at a single center in the UK and has the capacity for an extension cohort.
  • Recent research has shown that MDS patients who survive beyond two years are those with good NK cell activity (Tsirogianni et al 2019).
  • INKmune has been shown to boost the function of NK cells from MDS patients in laboratory experiments.
  • Two-stage priming of allogeneic Natural Killer cells for the treatment of patients with acute myeloid leukemia; a phase I trial.

 NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested

Wednesday, June 10, 2020 - 2:00pm

These published data indicate that our engineered haNK cells remain active in hypoxic conditions, which may be an important new mechanism of its anti-tumor activity.

Key Points: 
  • These published data indicate that our engineered haNK cells remain active in hypoxic conditions, which may be an important new mechanism of its anti-tumor activity.
  • Dr. Soon-Shiong continued, In addition, we are encouraged to observe anti-tumor activity in every cancer cell line tested by the investigators at NCI.
  • We have hypothesized that cancer undergoes a quantum change and adapts to the therapy administered, resulting in the selection of resistant, cancer stem-like cells.
  • NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies.